SOUTH SAN FRANCISCO, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today
announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 2016 UBS Global Healthcare Conference on
Wednesday, May 25th at 11:00 AM Eastern Time at The Grand Hyatt in New York City.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page
in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug
development organization committed to improving the lives of people with cancer and is currently pursuing regulatory approval in
Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients
aged 60 and older. In addition, the company is advancing its kinase-inhibitor pipeline of novel targeted therapies into the
clinic.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717
